1 Comment
author

1. Biotech (and longevity) is a super massive blackhole sucking in some of the smartest founders and investors -- many from backgrounds outside of biology. Expats from computer science and physics seem very common here.

I'm curious to know what percentage of my readers come from a background in biology or biotech or elsewhere. Were you familiar with all the different therapeutic modalities beforehand?

2. Longevity VCs are projecting 20 - 30% IRR-- VC funds see higher returns from early stage investing.

As an investor, what kind of returns are you expecting from your longevity biotech portfolio? What is your time horizon?

Let me know in the comments!

Expand full comment